Kari-Ann Takano
Kari-Ann Takano
I graduated from UC Davis with a B.S. in Microbiology. During my undergraduate studies, I became involved in research trying to better define the immune defense against lipopolysaccharides. After graduating, I worked at Kite Pharma in El Segundo, California, performing routine testing of commercial and clinical CAR-T cell therapy products for patients with B cell malignancies. Longing to return to research and academia, I was then employed as a research associate and lab manager at UCLA, specializing in creating highly specific lentiviral vectors.
I am currently a Ph.D. student in the BISI program studying the lethal synergism that occurs between Influenza A virus and Streptococcus pneumoniae.
Advisor(s)
Latest Papers
Phosphatidylserine receptors TIM-1 and AXL mediate tick-borne Powassan virus entry
|
iScience
Author(s): Maria Daskou, Anne K. Zaiss, Arjit Vijey Jeyachandran, et. al
UMD Author(s): Kari-Ann Takano
Envelope protein-specific B cell receptors direct lentiviral vector tropism in vivo
|
MOLECULAR THERAPY
Author(s): Kari-Ann Takano, Anita A.L. Wong, Rebecca Brown, et. al
UMD Author(s): Kari-Ann Takano
Replication-Deficient Zika Vector-Based Vaccine Provides Maternal and Fetal Protection in Mouse Model
|
Microbiology Spectrum
Author(s): Gustavo Garcia, Nikhil Chakravarty, Angel Elma Abu, et. al
UMD Author(s): Kari-Ann Takano